The purpose of this study is to compare the usual chemo-immunotherapy treatment for triple negative breast cancer to a shorter chemo-immunotherapy treatment that uses fewer drugs. Learn more about the S2212/SCARLET trial or call the Cancer Research Office at Reading Hospital at 484-628-8193.
S2212/SCARLET
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
